| ROS1 rearrangements define a unique molecular class of lung cancers K Bergethon, AT Shaw, SHI Ou, R Katayama, CM Lovly, NT McDonald, ... Journal of clinical oncology 30 (8), 863, 2012 | 1937 | 2012 |
| Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology DS Ettinger, DE Wood, DL Aisner, W Akerley, J Bauman, LR Chirieac, ... Journal of the National Comprehensive Cancer Network 15 (4), 504-535, 2017 | 1181 | 2017 |
| Mechanisms of receptor tyrosine kinase activation in cancer Z Du, CM Lovly Molecular cancer 17, 1-13, 2018 | 835 | 2018 |
| NCCN guidelines insights: non–small cell lung cancer, version 2.2021: featured updates to the NCCN guidelines DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, ... Journal of the National Comprehensive Cancer Network 19 (3), 254-266, 2021 | 784 | 2021 |
| Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, ... Journal of the National Comprehensive Cancer Network 20 (5), 497-530, 2022 | 698 | 2022 |
| NCCN guidelines insights: non–small cell lung cancer, version 1.2020: featured updates to the NCCN guidelines DS Ettinger, DE Wood, C Aggarwal, DL Aisner, W Akerley, JR Bauman, ... Journal of the National Comprehensive Cancer Network 17 (12), 1464-1472, 2019 | 667 | 2019 |
| Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors D Westover, J Zugazagoitia, BC Cho, CM Lovly, L Paz-Ares Annals of oncology 29, i10-i19, 2018 | 563 | 2018 |
| Acquired Resistance to KRASG12C Inhibition in Cancer MM Awad, S Liu, II Rybkin, KC Arbour, J Dilly, VW Zhu, ML Johnson, ... New England Journal of Medicine 384 (25), 2382-2393, 2021 | 556 | 2021 |
| First-line nivolumab plus ipilimumab in advanced non–small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers N Ready, MD Hellmann, MM Awad, GA Otterson, M Gutierrez, JF Gainor, ... Journal of Clinical Oncology 37 (12), 992, 2019 | 538 | 2019 |
| Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy DB Johnson, MV Estrada, R Salgado, V Sanchez, DB Doxie, SR Opalenik, ... Nature communications 7 (1), 10582, 2016 | 506 | 2016 |
| NCCN guidelines insights: non–small cell lung cancer, version 5.2018 DS Ettinger, DL Aisner, DE Wood, W Akerley, J Bauman, JY Chang, ... Journal of the National Comprehensive Cancer Network 16 (7), 807-821, 2018 | 502 | 2018 |
| Non–small cell lung cancer, version 2.2013 DS Ettinger, W Akerley, H Borghaei, AC Chang, RT Cheney, LR Chirieac, ... Journal of the National Comprehensive Cancer Network 11 (6), 645-653, 2013 | 496 | 2013 |
| Targeted next generation sequencing identifies markers of response to PD-1 blockade DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ... Cancer immunology research 4 (11), 959-967, 2016 | 470 | 2016 |
| Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases EE Vokes, N Ready, E Felip, L Horn, MA Burgio, SJ Antonia, OA Frontera, ... Annals of oncology 29 (4), 959-965, 2018 | 459 | 2018 |
| NCCN guidelines insights: non–small cell lung cancer, version 4.2016 DS Ettinger, DE Wood, W Akerley, LA Bazhenova, H Borghaei, ... Journal of the National Comprehensive Cancer Network 14 (3), 255-264, 2016 | 455 | 2016 |
| Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations YY Janjigian, EF Smit, HJM Groen, L Horn, S Gettinger, DR Camidge, ... Cancer discovery 4 (9), 1036-1045, 2014 | 428 | 2014 |
| Non–small cell lung cancer DS Ettinger, W Akerley, H Borghaei, AC Chang, RT Cheney, LR Chirieac, ... Journal of the National Comprehensive Cancer Network 10 (10), 1236-1271, 2012 | 426 | 2012 |
| Burnout and career satisfaction among US oncologists TD Shanafelt, WJ Gradishar, M Kosty, D Satele, H Chew, L Horn, B Clark, ... Journal of Clinical Oncology 32 (7), 678, 2014 | 417 | 2014 |
| Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133) SV Liu, M Reck, AS Mansfield, T Mok, A Scherpereel, N Reinmuth, ... Journal of Clinical Oncology 39 (6), 619, 2021 | 410 | 2021 |
| Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung … YK Chae, A Arya, W Iams, MR Cruz, S Chandra, J Choi, F Giles Journal for immunotherapy of cancer 6, 1-27, 2018 | 410 | 2018 |
Leora HornVanderbilt UniversityVerified email at vumc.org
